Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal

Resverlogix Corp. (TSX:RVX) reported the acceptance for publication of a manuscript titled: “RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease,” in the journal “Atherosclerosis”.
According to the company’s press release:

The key information in the manuscript details some of the beneficial actions of apabetalone (RVX-208), a bromodomain extra-terminal (BET) protein inhibitor for treating high-risk cardiovascular disease (CVD) patients. The data presented emphasises not only that apabetalone (RVX-208) raises the levels of ApoA-I and HDL, but also that the epigenetic actions of this BET inhibitor can modulate several factors known to be major contributors to CVD risk.

Dr. Norman C.W. Wong, chief scientific officer of Resverlogix stated:

We are pleased to have our data peer reviewed and published in the Atherosclerosis journal. This additional recognition helps to further confirm the importance of epigenetics in successfully modulating key CVD pathways.

Click here to view the full press release.